News | Radiation Therapy | September 14, 2017

Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017

Studies presented will explore innovative treatment approaches, and ways to enhance patient quality-of-life and well-being

Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017

September 14, 2017 – The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San Diego, will feature advances in cancer research, including reports from phase II and III clinical trials. Studies that examine innovative treatments, such as immunotherapy, mental health influences on cancer outcomes, and optimal radiation dosing and sequencing, will also be presented at the largest meeting for the field of radiation oncology.

The meeting is expected to attract more than 11,000 attendees to the San Diego Convention Center. Researchers selected for the press program will share their findings in a series of news briefings and webcast live to registered press. The schedule is as follows:

The Science of Radiation Oncology: Innovative Approaches
Sunday, Sept. 24, 1:00 p.m. – 2:00 p.m. Pacific time; moderator Brian Czito, M.D., FASTRO, Duke University

Quality Care in Radiation Oncology: Refining Treatments
Monday, September 25, 11:00 a.m. – 12:00 p.m. Pacific time; moderator, Paul Harari, M.D., FASTRO, ASTRO President-elect, University of Wisconsin

The Healing Art of Radiation Oncology: Patient Well-being
Tuesday, September 26, 1:00 p.m. – 2:00 p.m. Pacific time; moderator, Brian Kavanagh, M.D., MPH, FASTRO, ASTRO President, University of Colorado

In addition, the meeting will feature keynote addresses from Richard D. Zane, M.D., FAAEM, chief innovation officer for the University of Colorado Health System; Lucy Kalanithi, M.D., FACP, widow of Paul Kalanithi, M.D., the best-selling author of “When Breath Becomes Air,” with Heather Wakelee, M.D., Paul’s oncologist; and Vinay K. Prasad, M.D., MPH, an assistant professor of medicine at the Oregon Health and Science University.

During the four-day meeting, more than 200 exhibitors will demonstrate cutting-edge technology and medical device innovations for radiation oncology.

For more information: www.astro.org

Related Content

Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.
Proton therapy has evolved, and future predictions include smaller systems, more sophisticated proton dosimetry and devices that manipulate the proton beam
Feature | Proton Therapy | July 06, 2020 | By Minesh Mehta, M.D.
The field of proton...